CME Group CFO granted 4,088 restricted shares

CME’s President and CFO received a new restricted stock grant while surrendering shares to cover tax withholding on prior awards.

Rhea-AI Filing Summary

CME GROUP INC. (CME) reported insider equity activity by President and CFO Lynne Fitzpatrick. On September 15, 2026, she received a grant of 4,088 shares of Class A common stock as restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service. On September 15 and 16, 2026, a total of 1,340 shares were surrendered to the issuer to satisfy tax withholding obligations upon vesting of previously granted restricted stock, at reference prices of $275.09 and $272.46 per share; no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

5 transactions reported

Mixed 5 txns

Insider Fitzpatrick Lynne

Role President and CFO

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock Class A F2	359	$272.46	$98K
Grant/Award	Common Stock Class A F1	4,088	$275.09	$1.12M
Tax Withholding	Common Stock Class A F2	249	$275.09	$68K
Tax Withholding	Common Stock Class A F2	275	$275.09	$76K
Tax Withholding	Common Stock Class A F2	457	$275.09	$126K

Holdings After Transaction: Common Stock Class A — 26,661 shares (Direct)

Footnotes (2)

1. F1. Represents a grant of restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service.
2. F2. Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person.

Key Figures

Restricted stock grant: 4,088 shares Tax-withholding share surrenders: 1,340 shares Grant reference price: $275.09 per share +3 more

6 metrics

Restricted stock grant 4,088 shares Grant of Class A common stock on September 15, 2026

Tax-withholding share surrenders 1,340 shares Shares surrendered to issuer for tax withholding on September 15–16, 2026

Grant reference price $275.09 per share Value used for the 4,088-share restricted stock grant on September 15, 2026

Tax-withholding price (Sept. 16) $272.46 per share Reference price for 359 shares surrendered on September 16, 2026

Vesting schedule 4 installments Restricted stock vests in four equal annual installments, subject to continued service

Transactions reported as tax withholding 4 transactions Four code F dispositions for tax withholding obligations

Key Terms

restricted stock, Omnibus Stock Plan, tax withholding obligations, shares surrendered to the Issuer

4 terms

restricted stock financial

"Represents a grant of restricted stock under the CME Group Omnibus Stock Plan"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

Omnibus Stock Plan financial

"grant of restricted stock under the CME Group Omnibus Stock Plan"

tax withholding obligations financial

"satisfy tax withholding obligations in connection with the vesting"

shares surrendered to the Issuer financial

"Represents shares surrendered to the Issuer to satisfy tax withholding"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity award did CME (CME) grant to President and CFO Lynne Fitzpatrick?

She received a grant of 4,088 shares of Class A common stock as restricted stock on September 15, 2026, under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service.

How many CME (CME) shares were surrendered for tax withholding in this Form 4?

A total of 1,340 shares of CME Class A common stock were surrendered to the issuer to satisfy tax withholding obligations related to the vesting of previously granted restricted stock.

On what dates did the CME (CME) tax-withholding share surrenders occur?

Shares were surrendered on September 15, 2026 and September 16, 2026 to satisfy tax withholding obligations in connection with the vesting of earlier restricted stock awards.

What prices are associated with Lynne Fitzpatrick’s CME (CME) transactions?

The restricted stock grant used a reference value of $275.09 per share. Tax-withholding share surrenders used reference prices of $275.09 per share on September 15, 2026 and $272.46 per share on September 16, 2026.

Was a Rule 10b5-1 trading plan used for these CME (CME) insider transactions?

No. The filing indicates no Rule 10b5-1 trading plan for these reported transactions by President and CFO Lynne Fitzpatrick.

What type of CME (CME) security is involved in this Form 4?

All reported transactions involve CME’s Class A common stock, including the 4,088-share restricted stock grant and the 1,340 shares surrendered for tax withholding.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/17/2026 - 04:23 PM Accepted by SEC EDGAR 09/17/2026 - 04:22 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fitzpatrick Lynne

(Last) (First) (Middle)

20 SOUTH WACKER DRIVE

(Street)

CHICAGO ILLINOIS 60606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CME GROUP INC. [ CME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock Class A	09/15/2026		A(1)		4,088	A	$275.09	28,001	D
Common Stock Class A	09/15/2026		F(2)		249	D	$275.09	27,752	D
Common Stock Class A	09/15/2026		F(2)		275	D	$275.09	27,477	D
Common Stock Class A	09/15/2026		F(2)		457	D	$275.09	27,020	D
Common Stock Class A	09/16/2026		F(2)		359	D	$272.46	26,661	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service.

2. Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person.

Remarks:

	/s/ Elizabeth Hensen, as Attorney-in-Fact for Lynne Fitzpatrick	09/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)